Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Antibiotics Following Treatment of Neurogenic Overactive Bladder With Intradetrusor onabotulinumtoxinA
NCT04791579Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ciprofloxacin in urinary tract infection (UTI) (2 arms), sponsored by University of Alberta. Primary endpoint: Rate of Postoperative Urinary Tract Infection at 2 weeks. Started Feb 2025; status: recruiting.
02
Drugs
ciprofloxacin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT04791579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791579.